Serum-Oxford Covid-19 vaccine gets DCGI nod for phase 2, 3 clinical trials in India
4 years, 4 months ago

Serum-Oxford Covid-19 vaccine gets DCGI nod for phase 2, 3 clinical trials in India

Live Mint  

New Delhi: India's top drug regulator-- Drugs Controller General of India has granted permission to Serum Institute of India to conduct phase 2 and 3 human clinical trials in India on the potential COVID19 vaccine, a senior government official said. And after considering the data generated on the vaccine in phase-1, 2 of the Oxford University trial, the committee recommended granting permission to conduct phase 2, 3 clinical trials of COVISHIELD healthy adult subjects at risk in the country," the official said. Last week ANI had reported that the domestic pharma giant had made an application to DCGI for grant of permission to conduct phase 2, 3 clinical trials of coronavirus vaccine in India. Currently, phase 2, 3 clinical trials of the Oxford sponsor vaccine is ongoing in United Kingdom, phase 3 clinical trial in Brazil and phase 1, 2 clinical trials in South Africa.

India Trial Trials Sec Phase Oxford Serum Clinical Sii Gets Dcgi Vaccine Gets 3 Clinical Trials 3 Clinical Trial Vaccine Gets Dcgi  oxford  serumoxford  vaccine  gets  dcgi  trial  permission  covid19  india  safety  trials  clinical  official  phase  nod

History of this topic

Recent breakthrough in COVID-19 vaccination: Indian Immunologicals Ltd unveils first needle-free booster vaccine
3 months, 3 weeks ago

Recent breakthrough in COVID-19 vaccination: Indian Immunologicals Ltd unveils first needle-free booster vaccine

Hindustan Times  

In a recent development, Hyderabad-based Indian Immunologicals Ltd in collaboration with Griffith University in Australia has made a significant breakthrough in COVID-19 vaccination technology. Indian Immunologicals Ltd unveils first needle-free booster vaccine “This accomplishment signifies a major step forward in our battle against COVID-19. According to the press release, the innovative vaccine sports an attenuated formulation that uses advanced codon …

Serum Institute 'hopeful' of producing Mpox vaccine, says CEO Adar Poonawalla
4 months ago

Serum Institute 'hopeful' of producing Mpox vaccine, says CEO Adar Poonawalla

India TV News  

The Serum Institute of India announced on Tuesday that it is actively developing a vaccine for Monkeypox, with positive results anticipated within a year. Serum Institute's vaccine development efforts Serum Institute of India is working on a Monkeypox vaccine to address the global health emergency declared by the WHO. The vaccine is expected to be ready within a year, according …

Serum Institute of India's new 'high efficacy' malaria vaccine rolls out in Africa
5 months, 1 week ago

Serum Institute of India's new 'high efficacy' malaria vaccine rolls out in Africa

India Today  

A new “high efficacy” malaria vaccine co-developed by the Serum Institute of India and the University of Oxford was officially rolled out on Monday when Cote d’Ivoire in West Africa became the first country to begin administering R21/Matrix-M. In total, 15 African countries are expected to introduce malaria vaccines with Gavi support in 2024, and countries plan to reach around …

AstraZeneca's Covishield Showed Lowest Incidence of Side Effects in India Versus Globally, Says Top Govt Official
7 months, 2 weeks ago

AstraZeneca's Covishield Showed Lowest Incidence of Side Effects in India Versus Globally, Says Top Govt Official

News 18  

AstraZeneca’s vaccine has demonstrated the lowest incidence of side effects in India compared to the global average, a top government official involved in the national roll-out of Covid-19 vaccination told News18. “But only around 50 cases witnessed Thrombosis with Thrombocytopenia Syndrome — a rare side effect caused by the jab — of the 180 crore doses administered against 4 to …

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021
7 months, 2 weeks ago

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021

Live Mint  

New Delhi: The Serum Institute of India on Wednesday said it has stopped making and supplying covid-19 vaccine Covishield after AstraZeneca, the British drugmaker that helped develop the vaccine, announced it too was withdrawing its version of the jab worldwide. The development follows the launch of a class action suit in the UK over allegations that the UK vaccine caused …

Stopped manufacturing Covishield since December 2021, says Serum Institute
7 months, 2 weeks ago

Stopped manufacturing Covishield since December 2021, says Serum Institute

Hindustan Times  

Pune-based Serum Institute of India stopped manufacturing its anti-Covid-19 vaccine Covishield in 2021, according to a statement issued by the company on Wednesday after British-Swedish pharmaceutical manufacturer AstraZeneca announced it was withdrawing its vaccine against Covid, Vaxzevria, due to “commercial reasons” as demand for it decreased globally. Consequently, since December 2021, we have stopped the manufacturing and supply of additional …

Only 7 Out 10 Lakh May Face Clotting Risk Due to Covishield: Former ICMR Scientist
7 months, 3 weeks ago

Only 7 Out 10 Lakh May Face Clotting Risk Due to Covishield: Former ICMR Scientist

News 18  

Only seven to eight individuals out of 10 lakh, who receive the coronavirus vaccine Covishield, face the risk of experiencing a rare side effect known as thrombosis thrombocytopenia syndrome. India’s top epidemiologist, former ICMR scientist Dr Raman Gangakhedkar, said those who got this vaccine have “no risk at all”. Gangakhedkar, who is known for his simplistic approach to clearing complicated …

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns
7 months, 3 weeks ago

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns

India TV News  

In response to recent concerns regarding potential rare side effects associated with the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical company has underscored its unwavering commitment to patient safety while affirming the vaccine's overall safety profile. This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its Covid vaccine Covishield and Vaxzevria "can, in very rare cases, …

With State prod, India can be world leader in vaccines
10 months, 4 weeks ago

With State prod, India can be world leader in vaccines

Hindustan Times  

The World Health Organization activated its incident management support team as part of its emergency response framework on the emergence of a cluster of atypical pneumonia cases emerging from Wuhan, China, on January 1, 2020. India, the dark horse in the vaccine race, did the unexpected and against all odds, approving EUA to two vaccines — “made in India” Covishield …

Serum Institute of India joins global network to boost production of affordable outbreak vaccines
11 months ago

Serum Institute of India joins global network to boost production of affordable outbreak vaccines

The Hindu  

The Serum Institute of India will join a growing CEPI network of vaccine producers in the Global South to support more rapid, agile, and equitable responses to future disease outbreaks. The addition of SII to the CEPI manufacturing network will be a significant boost to vaccine production efforts in Global South regions, and take it a step closer to achieving …

COVID-19 Update: India records 260 new cases, total active at 1,828
1 year ago

COVID-19 Update: India records 260 new cases, total active at 1,828

Live Mint  

India reported 260 new cases of COVID-19, with active cases rising to 1,828, as per the latest data from the Union Health Ministry on December 18. Centre Urges States to Heighten Vigilance The central government has written to states and union territories, urging them to maintain "continuous vigilance" in light of the recent surge in COVID-19 cases and the identification …

Oxford-Serum institute malaria vaccine recommended for use by WHO
1 year, 2 months ago

Oxford-Serum institute malaria vaccine recommended for use by WHO

The Hindu  

The R21/Matrix-M malaria vaccine developed by the University of Oxford and the Serum Institute of India, leveraging Novavax’s adjuvant technology, has been recommended for use by the World Health Organisation after meeting required safety, quality and effectiveness standards, on Monday. According to information released by the Serum Institute, the WHO recommendation was based on pre-clinical and clinical trial data which …

A new regime: On the Emergency Use Authorisation regime in India and clinical trials
1 year, 5 months ago

A new regime: On the Emergency Use Authorisation regime in India and clinical trials

The Hindu  

Last week, the Drug Controller General of India cleared, under the provisions of ‘emergency use authorisation’, a new mRNA vaccine for COVID-19 developed by Pune-based Gennova Biopharmaceuticals, a pioneer in India in developing mRNA vaccines. More than evidence-based assessment, it was a technicality in India’s ‘New Drugs and Clinical Trials Rules, 2019’ that allowed EUA in India for COVID-19 vaccines. …

India urges G-20 countries to join vaccine research collaborative in wake of COVID vaccine inequity
1 year, 6 months ago

India urges G-20 countries to join vaccine research collaborative in wake of COVID vaccine inequity

The Hindu  

With the COVID-19 pandemic exposing the acute inequity in vaccine development and access, the Indian government is working in partnership with two leading global non-profits to convene and build consensus among the G-20 member States and others, for a proposed Global Vaccine Research Collaborative. “International cooperation is essential to advance vaccine development for emerging pathogens, and the G-20 can serve …

Explained | What are the problems with India’s clinical trials registry?
1 year, 8 months ago

Explained | What are the problems with India’s clinical trials registry?

The Hindu  

The speedy approval of Covid-19 vaccines during the SARS-CoV-2 pandemic spotlighted the importance of clinical trials. Hosted with the Indian Council of Medical Research’s National Institute of Medical Statistics, the CTRI is a free, online public-record system to register clinical trials being conducted in India. The CTRI is one of 17 public trial registries under the International Clinical Trials Registry …

Serum Institute could resume Covishield production as Covid cases rise
1 year, 8 months ago

Serum Institute could resume Covishield production as Covid cases rise

Live Mint  

The Serum Institute of India could resume production of the Covishield Covid-19 vaccine as infections rise in the country, a company spokesperson said on Wednesday. Dr Amitav Banerjee - an epidemiologist who leads DY Patil Medical College in Pune has earlier said that Covishield carried a ‘double whammy of risk’. Many would perhaps not know that Covishield carries a DNA …

Serum institute seeks to add Covovax on CoWIN portal as booster dose for adults
1 year, 8 months ago

Serum institute seeks to add Covovax on CoWIN portal as booster dose for adults

Hindustan Times  

Amid rising coronavirus cases, the Serum Institute of India has written a letter to the Union health ministry seeking the inclusion of its COVID-19 vaccine Covovax on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday. The letter was written by Prakash Kumar Singh, Director, Serum Institute of India on March 27, they said. …

‘The Vial’ trailer out: Manoj Bajpayee narrates History TV18's documentary on India’s Covid-19 vaccine journey
1 year, 9 months ago

‘The Vial’ trailer out: Manoj Bajpayee narrates History TV18's documentary on India’s Covid-19 vaccine journey

Firstpost  

India’s Covid-19 vaccination programme has proven to be the world’s largest but how did the nation, led by Prime Minister Narendra Modi, embark on this journey? To find out the details of a historic and unprecedented battle, check out History TV18’s documentary titled ‘The Vial – India’s Vaccine Story’ on March 24, 2023, at 8PM. ‘The Vial’ brings to life …

Covid vaccine mission is a lesson for the world
1 year, 9 months ago

Covid vaccine mission is a lesson for the world

Hindustan Times  

When Covid-19 began in early 2020, most experts predicted India could face disastrous consequences. India’s response to the pandemic highlighted the underlying strengths of our scientific and technological prowess Not only did India succeed in protecting its population, but it also sent vaccines to other countries, thus proving to the world its capability of developing the first-ever DNA vaccine and …

COVID-19: 3 lakh doses of intranasal vaccine iNCOVACC sent to hospitals, says Bharat Biotech's Krishna Ella
1 year, 10 months ago

COVID-19: 3 lakh doses of intranasal vaccine iNCOVACC sent to hospitals, says Bharat Biotech's Krishna Ella

India TV News  

COVID-19 vaccine : Bharat Biotech dispatched three lakh doses of its intranasal COVID-19 vaccine to some hospitals two days ago, the company's executive chairman Krishna Ella said on Sunday. "We dispatched three lakh doses of the world's first intranasal COVID-19 vaccine to some hospitals two days ago," Ella said. Establishing the UW-Madison Global One Health Centre holds great significance as …

India launches world’s 1st intranasal Covid vaccine: Check price, availability
1 year, 10 months ago

India launches world’s 1st intranasal Covid vaccine: Check price, availability

Hindustan Times  

The world's first made-in-India intranasal Covid-19 vaccine iNCOVACC, manufactured by Bharat Biotech, was launched on Thursday as the country marked its 74th Republic Day. Union health minister Mansukh Mandaviya launched the vaccine and emphasised India's vaccine manufacturing and innovation capability, which he said is appreciated all over the world. "As the world's first intranasal Covid-19 vaccine, this is a glorious …

Health minister Mandaviya launches Bharat Biotech's nasal Covid vaccine
1 year, 10 months ago

Health minister Mandaviya launches Bharat Biotech's nasal Covid vaccine

Hindustan Times  

Union Health Minister Mansukh Mandaviya and Science and Technology Minister Jitendra Singh launched Bharat Biotech's nasal Covid vaccine, iNCOVACC, on the occasion of Republic Day on Thursday. The nasal vaccine -- BBV154 -- had received the Drugs Controller General of India's approval in November for restricted emergency use among adults as a heterologous booster dose. According to a statement issued …

COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC
1 year, 10 months ago

COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC

India TV News  

COVID-19 nasal vaccine launch : Union Health Minister Dr Mansukh Mandaviya and Science and Technology Minister Jitendra Singh collectively launched 'iNCOVACC', the world's first made-in-India nasal vaccine on Thursday in the national capital. Who all were present: On the occasion of the launch, the Union Minister of State Science & Technology; Minister of State Earth Sciences; MoS PMO, Personnel, Public …

Bharat Biotech’s nasal vaccine likely to be launched on Jan 26
1 year, 11 months ago

Bharat Biotech’s nasal vaccine likely to be launched on Jan 26

Hindustan Times  

Bhopal: Bharat Biotech’s nasal Covid-19 vaccine iNCOVACC is expected to be launched on January 26, executive chairman Krishna Ella said at an event on Saturday. “Our nasal vaccine will be officially launched on January 26 on Republic Day,” Ella told students at the Maulana Azad National Institute of Technology in Bhopal, where the India International Science Festival, 2022, is being …

First Indian intranasal Covid vaccine by Bharat Biotech to be launched on Jan 26
1 year, 11 months ago

First Indian intranasal Covid vaccine by Bharat Biotech to be launched on Jan 26

India TV News  

Homegrown vaccine maker Bharat Biotech will launch its intranasal COVID-19 vaccine iNCOVACC, the first of its kind in India, on January 26, the company's chairman and managing director Krishna Ella said here on Saturday. In December, Bharat Biotech had announced that it would sell the intranasal vaccine for Rs 325 per shot for procurement by the government and Rs 800 …

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose
1 year, 11 months ago

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose

News 18  

The Drug Controller General of India has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Monday. Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India, had recently written to the DCGI for the approval …

No second Covid-19 booster dose required: Report
1 year, 11 months ago

No second Covid-19 booster dose required: Report

Live Mint  

There is no need to take a second booster dose against Covid-19 infection, news agency ANI reported on Tuesday citing government sources. According to the data by the Union Health Ministry, a total of 220.11 crore vaccine doses have been administered in the country, of which 95.13 crore have taken the second dose while only 22.41 crore of the population …

Staying prepared: On scaling up the pace of COVID-19 genome sequencing
1 year, 11 months ago

Staying prepared: On scaling up the pace of COVID-19 genome sequencing

The Hindu  

Three years after strict enforcement of its Zero-COVID strategy, China abandoned it abruptly, leading to a jump in cases each day — an estimated 250 million people were infected in 20 days in December, according to the media, overwhelming hospitals and crematoria. Though this variant was found in many countries, including India, months ago, there is fear that the uncontrolled …

Price of Bharat Biotech’s nasal Covid vaccine revealed. Details here
1 year, 11 months ago

Price of Bharat Biotech’s nasal Covid vaccine revealed. Details here

Live Mint  

Bharat Biotech's intranasal Covid vaccine has been approved by the Union Health Ministry as a booster dose for those aged 18 years and above according to reports will be available at ₹800+ GST+ hospital charges according to sources. The country’s first intranasal covid vaccine will be rolled out in the fourth week of January as a booster dose for those …

COVID-19: Centre approves Bharat Biotech's intranasal vaccine, to be available on CoWIN
2 years ago

COVID-19: Centre approves Bharat Biotech's intranasal vaccine, to be available on CoWIN

Firstpost  

The needle-free vaccine will be available at private centres. It will be introduced on the Co-WIN platform on Friday evening New Delhi: Bharat Biotech’s intranasal COVID-19 vaccine has been approved by the Ministry of Health and Family Welfare for inclusion in the vaccination programme as a booster dose for those above 18 years of age, official sources said on Thursday. …

Indian Army issues advisory on Covid, asks defence personnel to take safety measures
2 years ago

Indian Army issues advisory on Covid, asks defence personnel to take safety measures

India TV News  

The Indian Army issued an advisory on Friday asking defence personnel to take up adequate measures to tackle COVID. The advisory asked them to take up measures such as the usage of face masks in closed or crowded places, practising hand sanitisation, and maintaining social distancing among others. Union Health Minister Dr Mansukh Mandaviya is set to hold a virtual …

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose
2 years ago

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose

News 18  

The Serum Institute of India has sought the drug regulator’s approval for market authorisation of its COVID-19 vaccine Covovax as a booster dose for those aged 18 years and above who have been administered two doses of Covishield or Covaxin, official sources said on Thursday. Prakash Kumar Singh, director, government and regulatory affairs, SII, submitted a market authorisation application for …

Three reasons India will not see a Covid-wave like China’s
2 years ago

Three reasons India will not see a Covid-wave like China’s

Hindustan Times  

The Union health ministry reviewed the Covid-19 situation in India on Wednesday in light of a surge in cases in China and other countries such as Japan, South Korea, Brazil and the United States. Since China is the only big country where cases are at an all-time high, it is important to consider if India is protected against the factors …

A concerning sequence: The Hindu Editorial on a new coronavirus strain and a spurt in cases in China
2 years ago

A concerning sequence: The Hindu Editorial on a new coronavirus strain and a spurt in cases in China

The Hindu  

The spurt in coronavirus cases reported out of China has triggered global alarm. India’s Health Ministry has issued a directive to States to send positive samples to the Indian SARS-CoV-2 Genomics Consortium to check for new, concerning strains. There is scarce monitoring and mask mandates for public gatherings, airports and railway stations have been removed everywhere; so, low numbers do …

India need not panic given excellent COVID-19 vaccination coverage: Adar Poonawalla
2 years ago

India need not panic given excellent COVID-19 vaccination coverage: Adar Poonawalla

The Hindu  

Serum Institute of India CEO Adar Poonawalla on Tuesday expressed concern over reports of a rising COVID-19 graph in China but said there is no need to panic as the vaccination coverage in India is excellent. Mr. Poonawalla's tweet came a day after the Union Health Ministry urged all states and UTs to ramp up the whole genome sequencing of …

'Rising Covid cases in China concerning,' says Serum Institute's Adar Poonawalla
2 years ago

'Rising Covid cases in China concerning,' says Serum Institute's Adar Poonawalla

Hindustan Times  

Raising concern on the rising COVID-19 cases in neighbouring China, Serum Institute of India CEO Adar Poonawala on Wednesday asked the people not to panic because of India's "excellent vaccination coverage and track record". Expressing concern over the spurt in Covid-19 cases in China, former Indian diplomat KP Fabian on Tuesday said, "over 60 per cent of China and 10 …

Bharat Biotech urges Centre to include its intranasal COVID vaccine in CoWIN portal
2 years ago

Bharat Biotech urges Centre to include its intranasal COVID vaccine in CoWIN portal

Deccan Chronicle  

Hyderabad: Bharat Biotech has requested the central government to include its intranasal COVID-19 vaccine iNCOVACC, in CoWIN portal to enable the recipients of the jab to get vaccination certificate. The company sources said Bharat Biotech is currently holding discussions with international “potential partners” who have approached the company for manufacturing and distribution of the intranasal vaccine globally. “Since iNCOVACC has …

Oxford, Serum initiative: Anti-malaria vaccine’s Phase 3 trials conclude
2 years ago

Oxford, Serum initiative: Anti-malaria vaccine’s Phase 3 trials conclude

Hindustan Times  

Oxford University and the Serum Institute of India have completed Phase 3 trials for the R21 anti-malarial vaccine in Africa, company officials said on Monday. “Phase-3 trial for R21, which is a cost-effective multi-stage malaria vaccine, is completed in Africa,” said Umesh Shaligram, executive director of Serum Institute of India, on Monday. The makers said that the aim of the …

World’s first intra-nasal vaccine for COVID gets CDSCO nod for restricted use
2 years ago

World’s first intra-nasal vaccine for COVID gets CDSCO nod for restricted use

Live Mint  

World's first intra-nasal vaccine for COVID developed by India has got approval from the Central Drugs Standard Control Organisation for restricted use in emergency situations in the age group of 18 and above. A press release from the vaccine maker said iNCOVACC, a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised SARS-CoV-2 spike protein, is the world's first …

What Makes India's Covid Vaccination Programme A Global Best Practice In Public Health
2 years, 1 month ago

What Makes India's Covid Vaccination Programme A Global Best Practice In Public Health

News 18  

On April 14, 2020, India’s Prime Minister made an appeal to scientists and researchers to take the lead in developing a vaccine against the coronavirus. The group was tasked with formulating an implementation strategy for the Covid-19 vaccine including the selection of vaccine candidates, procurement of vaccines, prioritisation of population groups for vaccination, enabling digital infrastructure, vaccine delivery platforms as …

Health Ministry not to procure fresh COVID-19 vaccines; surrenders ₹4,237 crore from vaccination budget
2 years, 2 months ago

Health Ministry not to procure fresh COVID-19 vaccines; surrenders ₹4,237 crore from vaccination budget

The Hindu  

The government’s COVID-19 vaccination programme is in its final leg with the Health Ministry deciding against procuring more vaccines as of now and surrendering ₹4,237 crore, or nearly 85% of the 2022-23 budget allocation for inoculation purposes, to the Finance Ministry. Official sources told PTI that more than 1.8 crore doses are still available with the governments at the Centre …

AstraZeneca Nasal Spray Vaccine for Covid-19 Suffers Setback in Early Trial
2 years, 2 months ago

AstraZeneca Nasal Spray Vaccine for Covid-19 Suffers Setback in Early Trial

News 18  

In a major setback, AstraZeneca and the University of Oxford’s joint trial for the nasal-spray version of the Nonreplicating viral vector vaccine against Covid-19 did not yield desired protection, reported Reuters on Tuesday. The University of Oxford said, “An antibody response in the respiratory mucous membranes was seen in only a minority of participants in the trial, which was in …

VINCOV-19, country’s first anti-dote for COVID, ready for phase 3 trials, market authorisation
2 years, 2 months ago

VINCOV-19, country’s first anti-dote for COVID, ready for phase 3 trials, market authorisation

The Hindu  

The University of Hyderabad and CSIR-Centre for Cellular & Molecular Biology in collaboration with VINS Bioproducts Limited, an immunological company based here, have announced the successful completion of phase 2 clinical trials of ‘VINCOV-19’, touted to be the country’s first antidote and a cure against SARS-CoV-2 virus. VINCOV-19 is now ready for market authorisation and for simultaneous phase 3 clinical …

Covid-19: India logs nearly 5,000 new infections, active cases drop below 45k
2 years, 3 months ago

Covid-19: India logs nearly 5,000 new infections, active cases drop below 45k

Live Mint  

India has witnessed a marginal decline in daily Covid-19 cases on Saturday with country recording 4,912 new infections in the past 24 hours, according to an update given by the Ministry of Health and Family Welfare. The country conducted 3,03,888 Covid tests in the last 24 hours, with the total number of tests conducted so far at 89.33 crore. The …

Will Two ‘Made-in-India’ Vaccines Be the New Covid Boosters? News18 Decodes Differences
2 years, 3 months ago

Will Two ‘Made-in-India’ Vaccines Be the New Covid Boosters? News18 Decodes Differences

News 18  

India will soon roll out mRNA shots and intranasal vaccines, which will be available on CoWIN, and can be used as boosters against Covid-19. India’s first mRNA shot is only the third mRNA vaccine to be approved for Covid-19 in the world after Pfizer and Moderna. But mortality will be reduced.” Sharing a study of the intranasal vaccines under clinical …

Bharat Biotech’s intra-nasal COVID vaccine gets emergency use approval
2 years, 3 months ago

Bharat Biotech’s intra-nasal COVID vaccine gets emergency use approval

The Hindu  

Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 recombinant nasal vaccine has been approved by Central Drugs Standard Control Organisation for primary immunization against COVID-19 in 18+ age group for restricted use in emergencies, Health Minister Mansukh Mandaviya tweeted on Tuesday. Dr. Krishna Ella, chairman and managing director, Bharat Biotech, said: “iNCOVACC will be a global game changer in intra-nasal vaccines technology and delivery …

India's First Nasal Vaccine for Covid-19, Made by Bharat Biotech, Cleared for Emergency Use
2 years, 3 months ago

India's First Nasal Vaccine for Covid-19, Made by Bharat Biotech, Cleared for Emergency Use

News 18  

Bharat Biotech has been given an emergency use authorisation by India’s drug regulator, the Drug Controller General of India, for its intranasal Covid-19 vaccine, Union Health Minister Dr Mansukh Mandaviya tweeted on Tuesday. Big Boost to India's Fight Against COVID-19!Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted …

Covid-19: India's first intranasal vaccine by Bharat Biotech gets DCGI approval
2 years, 3 months ago

Covid-19: India's first intranasal vaccine by Bharat Biotech gets DCGI approval

India TV News  

The Bharat Biotech on Tuesday got emergency use authorisation from the Drugs Controller General of India for the Intranasal Covid-19 vaccine. Union Minister of Health and Family Welfare Mansukh Mandaviya termed it a 'Big boost' to India's fight against Covid-19. Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 recombinant nasal vaccine approved by CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for …

Monkeypox vaccines: India puts emergency buying on hold for now - here’s why
2 years, 3 months ago

Monkeypox vaccines: India puts emergency buying on hold for now - here’s why

Live Mint  

According to those with knowledge of the situation, India has chosen to delay purchasing the monkeypox vaccine on an emergency basis for the time being because the number of cases reported across the nation has not increased. Serum Institute of India, one of the first organisations to express interest in bringing the monkeypox vaccine into India, put its proposal on …

Cervical cancer vaccine to be launched in few months
2 years, 3 months ago

Cervical cancer vaccine to be launched in few months

Firstpost  

Initially, the vaccine will be made available through the government channel and from next year onwards some private partners would be involved too New Delhi: India’s first indigenously developed quadrivalent Human Papilloma Virus vaccine for the prevention of cervical cancer will be launched in a few months and made available to the people in an affordable price range of Rs …

Discover Related